Võrdle meetodeid
Vaata valitud meetodeid kõrvuti; erinevad read on esile tõstetud.
| Meta-analüütiline II faasi kliiniline uuring× | Võrkelementanalüüs× | |
|---|---|---|
| Valdkond≠ | Epidemioloogia | Tõendite süntees |
| Perekond | Process / pipeline | Process / pipeline |
| Tekkeaasta≠ | 2000s–2010s | 2002 |
| Looja≠ | Developed within clinical epidemiology and oncology statistics; key contributions by Sutton, Warmuth, and colleagues | Lumley (2002) |
| Tüüp≠ | Hybrid clinical trial / meta-analytic design | Method |
| Algallikas≠ | Warmuth, M., & Hinzmann, B. (2013). Phase II trials in oncology: From the statistical design of trials to the meta-analysis of the results. Onkologie, 36(9), 555–564. link ↗ | Lumley, T. (2002). Network meta-analysis for indirect treatment comparisons. Statistics in Medicine, 21(16), 2313–2324. DOI ↗ |
| Rööpnimetused≠ | MA-Phase II, meta-analytic single-arm trial, pooled Phase II design, Phase II meta-analysis | Mixed Treatment Comparison, MTC, Indirect Comparison Meta-Analysis |
| Seotud≠ | 2 | 1 |
| Kokkuvõte≠ | A meta-analytic Phase II clinical trial integrates individual or aggregate data from multiple single-arm or small Phase II studies into a unified meta-analytic framework. Rather than relying on a single underpowered trial to screen for activity, this design pools evidence across comparable cohorts to obtain a more reliable estimate of treatment response, enabling better-informed go/no-go decisions before committing to a large Phase III randomized trial. | Network meta-analysis (NMA) is a systematic method for comparing multiple interventions simultaneously within a single analytical framework, incorporating both direct evidence (head-to-head trials) and indirect evidence (comparisons via common comparators). First formalized by Lumley in 2002, NMA allows researchers to rank treatments and quantify comparative effectiveness even when some treatment pairs have never been directly studied. |
| ScholarGateAndmestik ↗ |
|
|